Agenus traded at $2.63 this Friday January 27th, increasing $0.19 or 7.79 percent since the previous trading session. Looking back, over the last four weeks, Agenus gained 21.20 percent. Over the last 12 months, its price fell by 0 percent. Looking ahead, we forecast Agenus to be priced at 2.61 by the end of this quarter and at 2.36 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.63
Daily Change
7.79%
Yearly
0%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 146.28 -1.12 -0.76% 6.06%
Agenus 2.63 0.19 7.79% 0%
Amgen 253.65 -1.23 -0.48% 10.70%
AstraZeneca 10,622.00 -22.00 -0.21% 21.16%
Bristol-Myers Squibb 72.44 -0.54 -0.74% 11.60%
Celldex Therapeutics 46.25 0.42 0.92% 59.37%
CSL 294.70 -1.42 -0.48% 14.44%
Dynavax Technologies 11.84 0.06 0.51% -6.03%
Gilead Sciences 83.70 0.11 0.13% 21.55%
GlaxoSmithKline 1,410.00 4.80 0.34% -15.11%
Glaxosmithkline 35.30 -0.04 -0.11% -21.99%
Immunogen 4.77 0.06 1.17% -9.06%
Incyte Corp 85.70 -0.31 -0.36% 15.45%
J&J 168.23 -0.66 -0.39% -2.07%
Karyopharm Therapeutics 3.18 0.05 1.60% -62.76%
Eli Lilly 342.09 -5.91 -1.70% 39.57%
MacroGenics 5.74 -0.18 -3.04% -51.64%
Merck 190.40 -2.10 -1.09% -0.34%
Merck & Co 105.38 -1.49 -1.39% 30.26%
Novartis 82.58 -0.10 -0.12% 4.04%
Novavax 11.29 0.31 2.82% -86.38%
Northwest Biotherapeutics 0.72 -0.01 -1.23% -19.48%
Pfizer 43.79 -0.46 -1.04% -19.40%
Regeneron Pharmaceuticals 742.97 0.53 0.07% 18.89%
Rigel Pharmaceuticals 1.80 -0.07 -3.74% -25.00%
Sangamo BioSciences 3.58 0.13 3.77% -37.30%
Veracyte 26.03 -0.03 -0.12% -3.88%
Intrexon 1.64 0.02 1.23% -33.33%

Indexes Price Day Year
USND 11622 109.30 0.95% -15.60%
US2000 1911 8.39 0.44% -2.90%

Agenus
Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.